Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby M, Thudium KB, Korman AJ, Ulmert D, Thorek DL, DeWeese TL, Drake CG.

Clin Cancer Res. 2018 Jun 13. pii: clincanres.3427.2017. doi: 10.1158/1078-0432.CCR-17-3427. [Epub ahead of print]

PMID:
29898992
2.

Impact of histological subtype on the prognosis of patients undergoing surgery for colon cancer.

Bagante F, Spolverato G, Beal E, Merath K, Chen Q, Akgül O, Anders RA, Pawlik TM.

J Surg Oncol. 2018 Mar 25. doi: 10.1002/jso.25044. [Epub ahead of print]

PMID:
29574929
3.

Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.

Adler BL, Pezhouh MK, Kim A, Luan L, Zhu Q, Gani F, Yarchoan M, Chen J, Voltaggio L, Parian A, Lazarev M, Lauwers GY, Pawlik TM, Montgomery EA, Jaffee E, Le DT, Taube JM, Anders RA.

J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.

PMID:
29464806
4.

Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.

Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL.

Science. 2018 Feb 2;359(6375):592-597. doi: 10.1126/science.aah3648. Epub 2018 Feb 1.

5.

Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series.

Weeks SR, Sun Z, McCaul ME, Zhu H, Anders RA, Philosophe B, Ottmann SE, Garonzik Wang JM, Gurakar AO, Cameron AM.

J Am Coll Surg. 2018 Apr;226(4):549-557. doi: 10.1016/j.jamcollsurg.2017.12.044. Epub 2018 Feb 2.

PMID:
29409981
6.

Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.

Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR.

Eur Radiol. 2018 Jul;28(7):3032-3040. doi: 10.1007/s00330-017-5198-9. Epub 2018 Jan 30.

PMID:
29383518
7.

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX.

J Clin Invest. 2018 Feb 1;128(2):580-588. doi: 10.1172/JCI96061. Epub 2018 Jan 16.

8.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

9.

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.

Shen YC, Ghasemzadeh A, Kochel CM, Nirschl TR, Francica BJ, Lopez-Bujanda ZA, Carrera Haro MA, Tam A, Anders RA, Selby MJ, Korman AJ, Drake CG.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):113-125. doi: 10.1038/s41391-017-0013-x. Epub 2017 Dec 4.

10.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

PMID:
29192647
11.

Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations.

Chianchiano P, Pezhouh MK, Kim A, Luchini C, Cameron A, Weiss MJ, He J, Voltaggio L, Oshima K, Anders RA, Wood LD.

Hum Pathol. 2018 Feb;72:127-134. doi: 10.1016/j.humpath.2017.11.011. Epub 2017 Nov 24.

PMID:
29180252
12.

Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.

Assarzadegan N, Montgomery E, Anders RA.

Virchows Arch. 2018 Jan;472(1):125-133. doi: 10.1007/s00428-017-2267-z. Epub 2017 Nov 15. Review.

PMID:
29143108
13.

Derivation of a disease-specific human induced pluripotent stem cell line from a biliary atresia patient.

Tian L, Eldridge L, Chaudhari P, Zhang L, Anders RA, Schwarz KB, Ye Z, Jang YY.

Stem Cell Res. 2017 Oct;24:25-28. doi: 10.1016/j.scr.2017.08.001. Epub 2017 Aug 8.

14.

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, Carrera-Haro MA, Ghasemzadeh A, Marciscano AE, Velarde E, Tam AJ, Thoburn CJ, Uddin M, Meeker AK, Anders RA, Pardoll DM, Drake CG.

Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2.

15.

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.

Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA.

Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19.

16.

Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.

Rucki AA, Xiao Q, Muth S, Chen J, Che X, Kleponis J, Sharma R, Anders RA, Jaffee EM, Zheng L.

Mol Cancer Ther. 2017 Nov;16(11):2399-2409. doi: 10.1158/1535-7163.MCT-16-0452. Epub 2017 Sep 1.

17.

Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM.

Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24.

18.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

19.

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM.

Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.

PMID:
28428193
20.

PBRM1 loss is a late event during the development of cholangiocarcinoma.

Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, Weiss MJ, Capelli P, Scarpa A, Argani P, Kapur P, Wood LD.

Histopathology. 2017 Sep;71(3):375-382. doi: 10.1111/his.13234. Epub 2017 Jun 22.

PMID:
28394406
21.

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. Epub 2016 Nov 11.

22.

Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ.

N Engl J Med. 2016 Nov 3;375(18):1749-1755.

23.

Microvascular Invasion in Hepatocellular Carcinoma and Liver Transplant.

Jakhete N, Saberi B, Jonassaint NL, Cosar AM, Luu H, Kim A, Anders RA, Philosophe B, Cameron AM, Gurakar A.

Exp Clin Transplant. 2016 Nov;14(Suppl 3):14-18.

PMID:
27805503
24.

Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study.

Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, Finegold MJ, Finn LS, Kim GE, Lovell MA, Magid MS, Melin-Aldana H, Ranganathan S, Shehata BM, Wang LL, White FV, Chen Z, Spino C; Childhood Liver Disease Research Network (ChiLDReN).

Am J Surg Pathol. 2016 Dec;40(12):1601-1615.

25.

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.

Robles AI, Olsen KS, Tsui DW, Georgoulias V, Creaney J, Dobra K, Vyberg M, Minato N, Anders RA, Børresen-Dale AL, Zhou J, Sætrom P, Nielsen BS, Kirschner MB, Krokan HE, Papadimitrakopoulou V, Tsamardinos I, Røe OD.

J Transl Med. 2016 Oct 19;14(1):295.

26.

Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation.

Xiao Q, Zhou D, Rucki AA, Williams J, Zhou J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, Wolfgang CL, Anders RA, Zheng S, Jaffee EM, Zheng L.

Cancer Res. 2016 Sep 15;76(18):5395-404. doi: 10.1158/0008-5472.CAN-15-3264. Epub 2016 Aug 5.

27.

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.

Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL.

Cancer Immunol Res. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4.

28.

Somatically Acquired LINE-1 Insertions in Normal Esophagus Undergo Clonal Expansion in Esophageal Squamous Cell Carcinoma.

Doucet-O'Hare TT, Sharma R, Rodić N, Anders RA, Burns KH, Kazazian HH Jr.

Hum Mutat. 2016 Sep;37(9):942-54. doi: 10.1002/humu.23027. Epub 2016 Jul 13.

29.

Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization.

Bai H, Zhu Q, Surcel A, Luo T, Ren Y, Guan B, Liu Y, Wu N, Joseph NE, Wang TL, Zhang N, Pan D, Alpini G, Robinson DN, Anders RA.

Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G396-411. doi: 10.1152/ajpgi.00027.2016. Epub 2016 May 26.

30.

Magnetoencapsulated human islets xenotransplanted into swine: a comparison of different transplantation sites.

Arifin DR, Valdeig S, Anders RA, Bulte JW, Weiss CR.

Xenotransplantation. 2016 May;23(3):211-21. doi: 10.1111/xen.12235. Epub 2016 May 26.

31.

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Topalian SL, Taube JM, Anders RA, Pardoll DM.

Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15. Review.

32.

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.

Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F, Anders RA, Pawlik TM.

Ann Surg Oncol. 2016 Aug;23(8):2610-7. doi: 10.1245/s10434-016-5101-y. Epub 2016 Mar 24.

PMID:
27012989
33.

Ganetespib radiosensitization for liver cancer therapy.

Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT.

Cancer Biol Ther. 2016 Apr 2;17(4):457-66. doi: 10.1080/15384047.2016.1156258.

34.

Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA.

Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3. Erratum in: Cancer Immunol Res. 2016 May;4(5):472.

35.

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.

Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ.

Gut. 2017 May;66(5):794-801. doi: 10.1136/gutjnl-2015-310839. Epub 2016 Jan 22.

36.

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.

Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL.

Ann Surg. 2016 Dec;264(6):1073-1081.

37.

PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

Bhaijee F, Anders RA.

JAMA Oncol. 2016 Jan;2(1):54-5. doi: 10.1001/jamaoncol.2015.3782. No abstract available.

PMID:
26561922
38.

A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.

Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y.

Biochem Biophys Res Commun. 2015 Dec 25;468(4):525-32. doi: 10.1016/j.bbrc.2015.10.031. Epub 2015 Oct 19.

PMID:
26482853
39.

LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.

Doucet-O'Hare TT, Rodić N, Sharma R, Darbari I, Abril G, Choi JA, Young Ahn J, Cheng Y, Anders RA, Burns KH, Meltzer SJ, Kazazian HH Jr.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):E4894-900. doi: 10.1073/pnas.1502474112. Epub 2015 Aug 17. Erratum in: Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E104.

40.

Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.

Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, DeMarzo AM, Drake CG.

Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.

41.

Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution.

Ewing AD, Gacita A, Wood LD, Ma F, Xing D, Kim MS, Manda SS, Abril G, Pereira G, Makohon-Moore A, Looijenga LH, Gillis AJ, Hruban RH, Anders RA, Romans KE, Pandey A, Iacobuzio-Donahue CA, Vogelstein B, Kinzler KW, Kazazian HH Jr, Solyom S.

Genome Res. 2015 Oct;25(10):1536-45. doi: 10.1101/gr.196238.115. Epub 2015 Aug 10.

42.

PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.

Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, Del Rio A, D'Santos C, Williams R, Chokshi S, Anders RA, Bubici C, Papa S.

Nat Commun. 2015 Aug 10;6:7882. doi: 10.1038/ncomms8882.

43.

Rotavirus Infects Human Biliary Epithelial Cells and Stimulates Secretion of Cytokines IL-6 and IL-8 via MAPK Pathway.

Clemente MG, Patton JT, Anders RA, Yolken RH, Schwarz KB.

Biomed Res Int. 2015;2015:697238. doi: 10.1155/2015/697238. Epub 2015 Jul 13.

44.

Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.

Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, Anders RA, Iacobuzio-Donahue CA, Hajjar KA, Maitra A, Jaffee EM, Zheng L.

Sci Signal. 2015 Aug 4;8(388):ra77. doi: 10.1126/scisignal.aaa5823.

45.

β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis.

Cai J, Maitra A, Anders RA, Taketo MM, Pan D.

Genes Dev. 2015 Jul 15;29(14):1493-506. doi: 10.1101/gad.264515.115. Epub 2015 Jul 20.

46.

Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders.

Gorgy AI, Jonassaint NL, Stanley SE, Koteish A, DeZern AE, Walter JE, Sopha SC, Hamilton JP, Hoover-Fong J, Chen AR, Anders RA, Kamel IR, Armanios M.

Chest. 2015 Oct;148(4):1019-1026. doi: 10.1378/chest.15-0825.

47.

Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP.

Chen Q, Zhang N, Xie R, Wang W, Cai J, Choi KS, David KK, Huang B, Yabuta N, Nojima H, Anders RA, Pan D.

Genes Dev. 2015 Jun 15;29(12):1285-97. doi: 10.1101/gad.264234.115.

48.

Yes-associated protein in the liver: Regulation of hepatic development, repair, cell fate determination and tumorigenesis.

Nguyen Q, Anders RA, Alpini G, Bai H.

Dig Liver Dis. 2015 Oct;47(10):826-35. doi: 10.1016/j.dld.2015.05.011. Epub 2015 May 22. Review.

49.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

50.

Pharmacological activation of myosin II paralogs to correct cell mechanics defects.

Surcel A, Ng WP, West-Foyle H, Zhu Q, Ren Y, Avery LB, Krenc AK, Meyers DJ, Rock RS, Anders RA, Freel Meyers CL, Robinson DN.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1428-33. doi: 10.1073/pnas.1412592112. Epub 2015 Jan 20.

Supplemental Content

Loading ...
Support Center